丹参酮ⅡA磺酸钠治疗冠心病心绞痛的药物经济学评价
x

请在关注微信后,向客服人员索取文件

篇名: 丹参酮ⅡA磺酸钠治疗冠心病心绞痛的药物经济学评价
TITLE: Pharmacoeconomic Evaluation of Sodium Tanshinone ⅡA Sulfonate in the Treatment of Angina Pectoris of Co- ronary Heart Disease
摘要: 目的:评估丹参酮ⅡA磺酸钠注射液联合常规用药对比常规用药治疗冠心病心绞痛的临床疗效和经济性。方法:以“丹参酮ⅡA磺酸钠“”丹参酮“”心绞痛“”SodiumtanshinoneⅡAsulfonate“”STS“”Danshentong“”Anginapectoris”等为中英文关键词,组合检索万方数据、中国知网、中国生物医学文献数据库、Cochrane图书馆、Medline、Embase、ISIWebofScience、BIOSISPreviews等数据库,检索时限均为建库起至2019年4月。筛选文献、提取资料后按照Cochrane系统评价员手册5.2.0偏倚风险工具对纳入的真实世界队列研究进行质量评价,采用Stata15.0软件进行Meta分析,并对结果进行发表偏倚分析;采用成本-效果分析进行药物经济学评价,并对结果进行单因素敏感性分析和概率敏感性分析。结果:共纳入29篇文献,共计31项研究、2857例患者。Meta分析结果显示,试验组患者的临床有效率[RR=1.23,95%CI(1.18,1.28),P<0.001]、心电图有效率[RR=1.29,95%CI(1.20,1.39),P<0.001]、心绞痛有效率[RR=1.22,95%CI(1.15,1.29),P<0.001]均显著高于对照组;两组患者的不良反应均较轻微;上述结果存在发表偏倚的可能性大。成本-效果分析显示,两种方案的增量成本-效果比为72.02;敏感性分析显示上述结果稳健。结论:对于冠心病心绞痛患者,丹参酮ⅡA磺酸钠注射液联合常规用药方案对比常规用药方案的疗效更优,成本也略高;当支付意愿高于7202元时,联合方案更具有成本-效果优势。
ABSTRACT: OBJECTIVE:To e valuate the clinical efficacy and economics of Sodium tanshinone Ⅱ A sulfonate injection combined with conventional medication versus conventional medication in the treatment of angina pectoris of coronary heart disease. METHODS :Using“Sodium tanshinone Ⅱ A sulfonate”“Danshentong”“angina pectoris ”as Chinese key words and “Sodium tanshinone Ⅱ A sulfonate”“Danshentong”“Angina pectoris ”as English keywords ,the studies were retrieved from Wanfang database ,CNKI,CBM,Cochrane Library ,Medline,Embase,ISI Web of Science and BIOSIS Previews during the inception to Apr. 2019. After literature screening and data extraction ,the included real world cohort studies were evaluated with bias risk tool of Cochrane systematic evaluator manual 5.2.0. Meta-analysis was conducted by using Stata 15.0 software,and publication bias of results was analyzed . The cost-effectiveness analysis was used for pharmacoeconomic evaluate ,and single factor sensitivity analysis and probability sensitivity analysis were carried out for the results of pharmacoeconomic evaluation. RESULTS : A total of 29 literatures were included ,involving 31 studies and 2 857 patients. Meta-analysis showed that clinical effective rate [RR =1.23,95%CI(1.18,1.28),P<0.001],ECG effective rate [RR =1.29,95%CI(1.20,1.39),P<0.001] and angina pectoris effective rate [RR =1.22,95%CI(1.15,1.29),P<0.001] of trial group were significantly higher than those of control group. The adverse reactions of the two groups were mild. The above results were likely to be biased in publication. Cost-effectiveness analysis showed that ICER was 72.02 of 2 groups. The sensitivity analysis showed that above results were stable. CONCLUSIONS : For patients with angina pectoris of coronary heart disease ,therapeutic efficacy of Sodium tanshinone ⅡA sulfonate injection combined with conventional medication is better that of conventional medication ,and the cost is also slightly higher. When the willingness to pay is higher than 7 202 yuan,the combination scheme has the advantage of cost-effectiveness.
期刊: 2020年第31卷第18期
作者: 刘洁,万楚川,陈磊,席晓宇
AUTHORS: LIU Jie,WAN Chuchuan ,CHEN Lei,XI Xiaoyu
关键字: 丹参酮ⅡA磺酸钠;冠心病心绞痛;Meta分析;疗效;成本-效果分析
KEYWORDS: Sodium tanshinone ⅡA sulfonate;Angina pectoris of coronary heart disease ;Meta-analysis;Therapeutic efficacy ;
阅读数: 99 次
本月下载数: 6 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!